 "Natco Q4 net soars nearly three-fold at Rs 176 cr, revenues up 46%")
The Hyderabad-based company's consolidated revenues increased 46 per cent to Rs 577.2 crore in the fourth quarter under review as compared to Rs 394.8 crore in the year ago period.
Natco's net profit for financial year 2016-17 has grown three times at Rs 484.9 crore from Rs 155.8 crore in the previous year. Its overall revenues have doubled to Rs 2,078.9 crore.
"The revenue and profit growth for the company during the financial year was driven primarily due to the sales of the generic Oseltamivir product in the US market and continued growth of domestic formulations business," Natco said in a statement.
Oseltamivir is a medication used to treat the bird flu virus in the human body.
The company's shares ended 5.7 per cent up at Rs 939.65, on the Bombay Stock Exchange on Tuesday.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app